
No guesswork. No Googling your results. A kit ships to your door, a best-in-class reference laboratory processes your sample, and a physician returns a clear personalized report. Not a page of numbers.
A baseline tells you where you are. Retesting every 3–6 months shows you where you’re going, and whether what you’re doing is working. Because at-home collection takes about 15 minutes with no clinic visit required, quarterly retesting is practical rather than aspirational.
Baseline
Start before any program. Understand your biology before you change it.
3-Month Check
Assess your response to any active protocol. Adjust before problems compound.
6-Month Panel
Confirm optimization. Verify trends are moving in the right direction.
Ongoing
Quarterly or biannual testing keeps your data current and your care precise.
At-home panels ship to your door starting at $159. Gender-specific marker sets for both. All processed by a national reference laboratory trusted by 2,000+ hospitals.

At-Home · Most Popular
$159
One-time purchase
Targeted hormone assessment delivered to your door. Covers the key hormonal, hematological, and inflammatory markers in a focused gender-specific draw. Collected with the FDA-cleared Tasso+ device. Results in 3–5 business days.
Best for
Monitoring a hormone protocol, investigating hormonal symptoms, or building a focused baseline of your endocrine health.
Markers included

At-Home · Comprehensive
$199
One-time purchase
Broad cross-system baseline delivered to your door. Covers cardiovascular, metabolic, kidney, liver, thyroid, hormonal, and inflammatory markers in a single gender-specific draw. Collected with the FDA-cleared Tasso+ device. Results in 3–5 business days.
Best for
A first-time comprehensive workup, annual wellness monitoring, or tracking metabolic progress across every major system.
Markers included
Transparent pricing · No hidden fees · HSA/FSA eligible
Purchasing both panels requires two Tasso+ devices (one per draw).
Most direct-to-consumer labs compete on the length of their marker list. We don’t. Every marker on a Crimson panel is there because it has a well-established evidence base, a clinically meaningful reference range, and a clear next step when it falls outside normal. Markers that don’t meet that bar aren’t on the panel.
Every Crimson marker is drawn from peer-reviewed literature and clinical guideline recommendations. We don't include markers because they're novel or because competitors do. We include them when there's a defined clinical response to an abnormal result.
All labs are ordered by licensed clinicians. The clinical team has full authority to identify red flags, diagnose conditions, and prescribe treatment when appropriate. That's a meaningful distinction from consumer lab services that return raw numbers without any clinical pathway attached.
A 150-marker panel is only valuable if you know what to do with each number. Crimson panels are scoped so that every result comes back with a clear interpretation and, when relevant, a defined clinical pathway. No raw outputs. No unexplained flags. No results that require you to go research what they mean.

Many of the markers on a Crimson panel require a fasting draw. At a clinic, that means scheduling an appointment, driving in hungry, waiting, and then getting through the draw before you can eat. With Tasso+, you apply the device before breakfast — the collection is done in 15 minutes, and you go about your morning.
The FDA-cleared Tasso+ device pulls a small blood sample from your upper arm. No vein, no clinic, minimal discomfort.
These categories cover the markers across all Crimson panels. Expand each to understand the specific markers and the clinical rationale for measuring them.
Research
Building the next generation of biomarkers to measure human function and extend healthspan at scale.
VO₂ max is the single strongest predictor of all-cause mortality, more predictive than blood pressure, cholesterol, or smoking status. Measuring it today requires specialized treadmill equipment, making it inaccessible for routine tracking.
Crimson is researching a blood-based biomarker panel that correlates with cardiorespiratory fitness, with the goal of making VO₂ max trackable through a standard blood draw alongside the rest of your panel.
#1
Predictor of all-cause mortality
Each MET increase in VO₂ max is associated with a 13% reduction in all-cause mortality and 18% reduction in cardiovascular mortality, independent of age, sex, or other risk factors.
Kokkinos P, et al. J Am Coll Cardiol. 2022;80(6):598–609. (n=750,000)
~1%
Annual decline without intervention
VO₂ max declines roughly 1% per year after age 30 without targeted training. The trajectory is measurable and modifiable with the right protocol.
Ross R, et al. Circulation. 2016;134(24):e653–e699. (AHA Scientific Statement)
“My A1C dropped from 6.1 to 5.4 in 90 days after adjusting my protocol based on the results. I had zero symptoms. I had no idea I was headed toward type 2.”
David R.
Baseline Panel · GLP-1 Protocol
“I'd been told my labs looked normal for three years. Crimson found my free testosterone and ferritin were both low-normal. Six weeks into the protocol, I felt completely different.”
Karen P.
Hormone Panel · Women's Health
Your results are yours. They are shareable with your primary care physician, any specialist, or any provider involved in your care. If your results indicate something that requires specialist evaluation (an endocrinologist, cardiologist, or other subspecialist), we will tell you and, when appropriate, facilitate the referral.
Shareable with your PCP and any specialist
Standard clinical format any provider can use
Referrals when results warrant specialist input
Baseline for any Crimson treatment program
Most people are surprised by at least one result. Start with a baseline; it’s the only way to know where you actually stand.
Get Your BaselineTakes 15 minutes. No clinic visit. HSA/FSA eligible.